ESR1 and neoplasm: The extent of surgical excision must be weighed against the risks, especially in patients of childbearing age [8], so some authors suggested treatment with gonadotropin-releasing hormone agonists as a neoadjuvant treatment to decrease the tumor size before surgery or as an adjuvant treatment to prevent recurrence in tumors, which are ER- and PR-positive [11].